Clinical Trials Logo

Clinical Trial Summary

ProCaLung is a national registry collecting radiation treatment parameters of patients having lung cancer that extends to mediastinal lymph nodes. The project includes a peer review activity. The purpose of this public health program is similar to an audit whose objective is to promote quality of radiation oncology in Belgium. It is run by Institut Jules Bordet on behalf of the College of Physicians for Radiotherapy Centers of the Belgian Health Federal Public Service, in close collaboration with the Belgian Cancer Registry. All Belgian radiotherapy centers are invited to participate in ProCaLung but their participation is not mandatory. The centers who accept to participate show a commitment to quality assurance as the radiotherapy-treatment-related parameters they generate will be analyzed to establish national statistics. It includes a peer-review process based on international guidelines for mediastinal nodes delineations given for informational purposes. The public interest program also collects technical parameters as they were planned and delivered during the course of chest radiation treatment. This includes the delineations of tumors, nodes and chest organs on simulation-CT images, PET/CT images, chest-CT images and the clinical information related to the lung cancer. Results/statistics will be published at the end of the project.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT04726358
Study type Observational [Patient Registry]
Source Jules Bordet Institute
Contact Luigi Moretti, MD, PhD
Phone +3225413800
Email Luigi.moretti@bordet.be
Status Recruiting
Phase
Start date October 1, 2021
Completion date March 1, 2025

See also
  Status Clinical Trial Phase
Recruiting NCT06120803 - Esomeprazole and Radiation Induced Esophagitis Phase 2
Recruiting NCT06075524 - Evaluation of Anti-PD-1 Therapy by Monitoring T Cell Responses in Melanoma, Lung and Other Cancer Types
Completed NCT04951063 - Fraction Dose Escalation of Hypo-fractionated Radiotherapy in LANSCLC Phase 1
Recruiting NCT03735095 - Endobronchial Ultrasound Guided Interstitial Photodynamic Therapy in Treating Patients With Locally Advanced Lung Cancer Phase 1/Phase 2
Recruiting NCT04680377 - Using Microbiome to Predict Durvalumab Toxicity in Post- Concurrent Chemoradiation Therapy (CCRT) NSCLC Patients